Upregulation and activation of epidermal growth factor receptor and/or urokinase-type plasminogen activator receptor in a variety of cancers have been shown to be associated with poor prognosis. High-molecular-weight kininogen can be hydrolysed by plasma kallikrein to bradykinin and cleaved high-molecular-weight kininogen (HKa). HKa and its domain 5 (D5) both have been shown to have potent anti-angiogenic activity. We now show that HKa blocks human prostate cancer cell (DU145) migration by 76.0 ± 2.4% at 300 nM and invasion by 78.0±12.9% at 11.1 nM. D5 inhibits tumor migration and invasion in a concentration-dependent manner. Stimulation by basic fibroblast growth factor (bFGF) or vascular endothelial growth factor results in clustering of urokinase-type plasminogen activator receptor (uPAR) and epidermal growth factor receptor (EGFR) on the surface of DU145 cells. The co-localization of uPAR and EGFR is prevented by HKa. Immunoprecipitation suggests that uPAR, EGFR and a5b1 integrin formed a ternary complex. Immunoblotting shows that HKa significantly decreases the bFGF-transactivated phosphorylation of EGFR at Tyr 1173 between 30 min and 4 h. The phosphorylation of extracellular signal-regulated kinase (ERK) and AKT, which are downstream effectors of EGFR, is also inhibited by HKa. These novel data indicate that HKa and D5 inhibit migration and invasion of human prostate cancer cells through an EGFR/uPAR pathway, suggesting the therapeutic potential of HKa and D5 to decrease metastasis of human prostate cancer.
Introduction
Urokinase plasminogen activator (uPA) is synthesized and secreted as a pro-enzyme, whose activation is markedly accelerated on binding with high affinity (B1 nM) to its receptor urokinase-type plasminogen activator receptor (uPAR) . uPAR is a glycophosphatidylinositol-anchored protein, consisting of three B90 amino-acid repeats D1, D2 and D3 (Nykjaer et al., 1998) . uPA and uPAR play a critical role in spread of prostate cancer. First, elevated serum levels of uPA and uPAR are directly correlated with the serum level of prostate-specific antigen and the development of the prostate cancer metastasis, and inversely correlated with overall survival rate among prostate cancer patients (Kirchheimer et al., 1985) . Second, the density of uPA and uPAR in prostate tumor tissues is significantly higher than in normal prostate from the healthy individuals (Miyake et al., 1999) . Finally, the binding of uPA to its receptor uPAR can activate downstream signaling molecules, including the mitogen-activated protein kinase, signal transducer and activator of transcription, and the Ras/extracellular signal-regulated kinase pathway, which, in turn, leads to cell proliferation, migration and invasion (Ma et al., 2001; Aguirre-Ghiso et al., 2003) .
Epidermal growth factor receptor (EGFR) and its family members play a pivotal role in tumor development, and their expression strongly affects the clinical outcome of cancer patients (Yarden, 2001; Hynes and Lane, 2005) . The EGFR family consists of four transmembrane receptors belonging to the receptor tyrosine kinase super family and includes EGFR (also known as ErbB1/HER-1), ErbB2/Neu/HER-2, ErbB3/ HER-3 and ErbB4/HER-4 (Schlessinger, 2002) . In prostate cancer, EGFR expression was detected in 18% of cancers and was significantly associated with high grade, advanced stage and high risk for prostatespecific antigen recurrence in univariate analysis (Po0.0001) (Schlomm et al., 2007) .
Epidermal growth factor receptor is a transducer of the urokinase receptor-initiated signal that is required for in vivo growth of a human carcinoma (Liu et al., 2002; Mamoune et al., 2004) . uPAR, EGFR and integrins form a ternary complex, which promotes cancer cell migration, invasion, proliferation and survival (Liu et al., 2002) . Specific ligands, such as uPA or EGF working through paracrine or autocrine loops are well-established activators of EGFR (Schlessinger, 2000) . In cells expressing very low levels of uPAR, which are dormant in vivo (Aguirre Ghiso et al., 1999) , the a5b1 integrin exists in an inactive state and associates poorly with EGFR. In spite of its high expression, under both basal conditions or after cell adhesion to fibronectin, EGFR is not phosphorylated. In contrast, in cells expressing high levels of uPAR, this receptor, in the presence of uPA, interacts frequently with and activates a5b1, leading to the formation of a multiprotein complex that contains FAK and EGFR, and that exhibits robust extracellular signal-regulated kinase (ERK) activation. These results unveil a model whereby highly malignant human carcinoma cells, through overexpression of uPAR, are able to subvert and utilize a tightly regulated EGFR pathway to gain matrix-derived proliferative advantage.
High-molecular-weight kininogen (HK) is a multifunctional plasma protein that plays important roles in many pathophysiological processes, such as fibrinolysis, thrombosis and inflammation (Colman et al., 1998; Colman, 1999) . Single-chain HK consists of six domains and is complexed in plasma with prekallikrein (Schmaier and McCrae, 2007) . On the endothelial cell surface, prekallikrein is cleaved by prolylcarboxpeptidase to kallikrein, which releases bradykinin from domain 4 (D4) of HK to generate two-chain high-molecularweight kininogen (HKa). HKa undergoes extensive conformational changes to expose D5 and inhibits angiogenesis through these anti-adhesive sites (Colman, 2006) . HKa and D5 bind uPAR and induce apoptosis in endothelial cells by disrupting uPAR association with integrins avb3 and a5b1 through cell detachment (Cao et al., 2004; Liu et al., 2008b) . uPAR mediates adhesion and signaling in endothelial cells by binding to vitronectin. D5 of HK binds the soluble uPAR receptor with 10-fold higher affinity than D3 (Mahdi et al., 2004) . Therefore, exposure of D5 in HKa is consistent with HKa having a higher affinity for uPAR than HK. In this study, we hypothesize that the binding of HKa and D5 to uPAR inhibits EGFR phosphorylation and would therefore inhibit tumor cell migration and invasion in prostate cancer.
Results

HKa and D5 inhibit migration and invasion of prostate cancer cell
Growth factors induce uPAR internalization by initially activating pro-uPA followed by complex formation with PAI-1 and interaction of the ternary complex uPAR/ uPA/PAI-1 with a member of the LDL receptor-like family (Prager et al., 2004) . During cell migration, uPAR is redistributed to focal adhesions at the leading edge either by lateral movement or by internalization and recycling of the receptor. We earlier showed (Liu et al., 2008a ) that binding of HKa or D5 to uPAR could prevent the process of uPAR internalization and inhibit endothelial cell migration. We postulated that HKa and D5 also would inhibit the migration of tumor cells expressing high levels of uPAR. We evaluated the inhibitory potential of HKa and D5 on a human prostate tumor cell line, DU145, which expresses high levels of uPAR (Liu et al., 2008b) . In Figure 1 , basic fibroblast growth factor (bFGF)-induced cell migration was significantly decreased to 24 ± 2.4% by HKa (300 nM), whereas D5 inhibition on cell migration at 33.3, 100 and 300 nM was 36 ± 0.6, 41 ± 3.4 and 50 ± 5.7%, respectively. The inhibition of cell migration (76±2.4%) by HKa (300 nM) is significantly greater than D5 (300 nM) (Po0.0015).
Urokinase plasminogen activator is synthesized as a 55-kDa single-chain proenzyme and converted into the two-chain active form by a single cleavage at Lys158-Ile159. uPA efficiently converts the inactive zymogen, plasminogen into the active serine protease, plasmin. Plasmin directly or indirectly cleaves ECM components including laminin, fibronectin, fibrin, vitronectin and collagen, which are the initial steps to invasion (Li and Cozzi, 2007) . We have shown that binding of HKa to uPAR could prevent the association of uPA and uPAR (Liu et al., 2008a) . We tested whether binding of HKa to uPAR could interfere with this process and therefore inhibit cell invasion. As shown in Figure 2 , HKa (11.1 nM) significantly inhibited neoplastic cell invasion by 78.0±12.9%, whereas D5 at 11.1, 33.3 and 100 nM inhibited DU145 cell invasion by 90.2±1.7, 98.9±0.6 and 99.9 ± 0.1%, respectively. These data showed that both HKa and D5 are potent inhibitors of tumor invasion and that the magnitude of their effects is similar.
HKa prevents the association of uPAR and EGFR in the presence of bFGF We have showed that prostate cancer cells expressed high levels of both uPAR and EGFR (Liu et al., 2008b) . EGFR is a transducer of the urokinase-receptorinitiated signal that is required for in vivo growth of a human carcinoma (Liu et al., 2002; Mamoune et al., 2004) . Recent data showed that uPAR, EGFR and integrins form a ternary complex, which promotes cancer cell migration, invasion, proliferation and survival (Liu et al., 2002) . We have observed that the binding of HKa and D5 to cells is mediated by uPAR in the presence of Zn þ þ (Pixley et al., 2003) . Thus, HKa and D5 could potentially inhibit the association of EGFR and uPAR in prostate cancer cells by targeting uPAR. In Figure 3a , expression of uPAR and EGFR in DU145 cells were determined by immunofluorescence. In the quiescent DU145 cells, uPAR and EGFR were partially co-localized (top panel). Stimulation with bFGF significantly enhanced the co-localization of uPAR and EGFR (middle panel). In contrast, the addition of HKa (100 nM) prevented the co-localization of uPAR and EGFR (bottom panel). Thus, HKa can block the association of uPAR and EGFR and therefore might inhibit uPAR and EGFR signaling pathways. Similar results were obtained in Figure 3b when vascular endothelial growth factor is used instead of bFGF.
HKa disrupts the complex of EGFR and uPAR in the presence of bFGF The data from Figure 3 indicated that uPAR and EGFR can form a complex in the presence of bFGF or vascular endothelial growth factor. We postulated that HKa could disrupt this complex. Thus, we performed experiments in which lysates of DU145 cells were immunoprecipitated with an antibody to EGFR and the precipitates were immunoblotted for uPAR ( Figure 4a ). The uPAR in cell lysates was precipitated by an antibody to the C-terminal of EGFR. HKa prevented the antibody to EGFR from precipitating uPAR by 74.8 ± 8.2% (Figure 4b ). The presence of EGFR was confirmed by probing the immunoprecipitates with anti-EGFR antibody.
It has been suggested that the association of uPAR and EGFR requires a5b1 integrin (Wang et al., 2005) . This observation raises the question whether uPAR directly binds to EGFR or through a5b1 integrin in prostate cancer cells. As shown in Figure 4c , antibodies to a5b1 and avb3 precipitated uPAR and EGFR from cell lysates, respectively. Consistent with our earlier observations (Cao et al., 2004; Liu et al., 2008b) , HKa prevented the antibody to a5b1 from precipitating uPAR by 67.4±9.7% and EGFR by 46.8±5.1% (Figure 4d ), whereas HKa only prevented the antibody to avb3 from precipitating uPAR by 45.1±6.0% ( Figure 4d ) but not EGFR. Reciprocal experiments showed that the antibody to EGFR precipitated a5b1 and avb3 integrins (Figure 4a ), suggesting that uPAR, EGFR and integrins formed a complex. HKa blocked the antibody to EGFR from precipitating a5b1 by 83.3 ± 12.3% (Figure 4b ), but not avb3. On the basis of the data above, we propose that uPAR, EGFR and a5b1 or avb3 form two different complexes. In one complex, uPAR bridges EGFR and a5b1 together, whereas in the other one avb3 brings uPAR and EGFR in close proximity. Thus, HKa can completely disrupt the EGFR-uPAR-a5b1 complex but only partially block the EGFR-avb3-uPAR complex became the binding of EGFR to avb3 is not inhibited by HKa.
HKa suppresses the signaling pathway of EGFR in the presence of bFGF Prevention of the association of uPAR and EGFR by HKa suggested that it might inhibit downstream signaling events through the EGFR pathway. Western blotting showed that HKa inhibited the phosphorylation of EGFR at Tyr 1173 ( Figure 5a ). The inhibition of EGFR phosphorylation by HKa (100 nM) was time dependent, 18.9 ± 6.7, 46.4 ± 8.0, 75.8 ± 9.9 and 89.5 ± 9.1% at 15, 30 min, 1 and 4 h, respectively (Figure 5b , top). The differences between the untreated group and HKa-treated group at 30 min, 1 and 4 h were significant. The phosphorylation of ERK and AKT (Ser 473) was also inhibited by HKa (Figure 5a ). The inhibition of ERK phosphorylation by HKa mimicked HKa inhibition of EGFR phosphorylation, which was 25.9 ± 27.1, 43.3 ± 5.7, 55.3 ± 6.5 and 93.9 ± 11.7 at 15, 30 min, 1 and 4 h, respectively (Figure 5b , middle). However, HKa almost completely prevented AKT phosphorylation from 15 min to 4 h. HKa inhibition on AKT phosphorylation was progressed with 67.9 ± 8.3, 74.5 ± 9.0, 80.7 ± 16.0 and 94.6 ± 10.3% at 15, 30 min, 1 and 4 h, respectively (Figure 5b , bottom).
AG 1478 inhibits migration and invasion of prostate cancer cell
Epidermal growth factor receptor regulates cell migration and invasion in a variety of cells. This observation was further confirmed by both migration and invasion assays as shown in Figure 6 , AG 1478, an EGFR inhibitor, concentration-dependently inhibited both migration ( Figure 6a ) and invasion ( Figure 6b ) of prostate cancer cells. AG 1475 at 33.3, 100 and 300 nM inhibited cell migration about 34.6±1.3, 50.5±2.3 and 68.7 ± 3.5%, respectively (Figure 6d , black bar). AG 1478 even more potently suppressed cell invasion about 88.1±17.3, 97.1±0.8 and 98.5±0.4% at 11.1, 33.3 and 100 nM, respectively (Figure 6d , white bar). Although HKa and AG 1478 inhibited cell migration, it was not potent as it did on cell invasion. We wondered if HKa and AG 1478 would synergistically inhibit cell migration. As shown in Figure 6c , combination of HKa (300 nM) plus AG 1478 (300 nM) almost completely inhibited cell migration. Inhibition of HKa plus AG 1478 was about 97.7% (Figure 6d, strip bar) .
This data confirm that EGFR plays a critical role in cell migration and invasion, whereas HKa inhibition of EGFR activation by disrupting the complex of uPAR and EGFR could suppress tumor cell migration and invasion, and therefore it predicts to inhibit tumor metastasis. Figure 3 HKa prevents the association of uPAR and EGFR. (a, b) Expression of uPAR and EGFR as monitored by immunofluorescence. Prostate cancer cells were grown on coverslips and starved for 2 h. Cells pretreated with or without 100 nM HKa for an additional hour. Cells were challenged with or without (a) bFGF (20 ng/ml) as well as (b) VEGF (20 ng/ml) for 30 min. Cells were fixed by 4.0% formaldehyde. Immunofluorescence was carried out as described in Materials and methods.
Figure 4
HKa disrupts the complex of uPAR, EGFR and integrins. (a) Prostate cancer cells were grown on 60 cm 2 dishes and treated with or without HKa (100 nM) for 4 h and harvested by adding extraction buffer. Immunoprecipitation procedures were performed as described in Materials and methods using an antibody to EGFR. Total a5b1, avb3 and uPAR were probed by corresponding antibodies. a-tubulin showed equal protein loading. (b) Total a5b1, avb3 and uPAR to EGFR were quantified by densitometry. Controls were set to 100%. Comparisons were made with control. Black column represents total a5b1 to EGFR. Stripped column represented total avb3 to EGFR. White column represents total uPAR to EGFR. Data were obtained from three independent experiments. Data plotted as mean ± s.e.m. ***Po0.005. (c) HKa disruption of the integrins, uPAR and EGFR was confirmed by reciprocal experiments. Immunoprecipitation procedures were performed as described in Materials and methods using antibodies to a5b1 or avb3. Total EGFR and uPAR were probed by corresponding antibodies. a-tubulin showed equal protein loading. (d) Total EGFR and uPAR to either a5b1 or avb3 were quantified by densitometry. Controls were set to 100%. Comparisons were made with control. Data were obtained from three independent experiments. Black column and white column represent that the immunoprecipitation were performed with the antibodies to a5b1 and avb3, respectively. Data plotted as mean ± s.e.m. ***Po0.005.
Discussion
The overexpression of uPAR and EGFR is associated with poor prognosis in patients with prostate cancer. We have earlier shown that HKa and D5 could inhibit cell motility and proliferation by binding to the D2 and D3 of uPAR. We also observed that the core sequence of HKa, which exerts its inhibitory effects on cell motility is G486-G496 (Liu et al., 2008b) . In this study, we show that HKa and D5 also inhibited both prostate cancer cell motility and invasion. We hypothesize that this observation is because of the binding of HKa to uPAR. As shown in Figures 3 and 4 , HKa prevents the association of uPAR and EGFR and disrupts the complex of EGFR and uPAR. Finally, we show that HKa inhibits the activation of ERK and PI3 kinase signaling by disrupting the complex of uPAR, EGFR with integrins.
The X-ray structure of uPAR has been solved recently and has shown that uPAR binds uPA in a pocket comprised by all of its three domains. This conformation presents the entire external surface of uPAR free for interactions with other proteins, for example, integrins, EGFR and N-formyl-peptide receptor (FPR) (Li and Cozzi, 2007) . We initially observed that prostate cancer expressed high levels of uPAR and EGFR (Liu et al., 2008b) . We tested whether HKa could inhibit the EGFR-signaling pathway because HKa can bind to D2 and D3 of uPAR. Immunofluorescence showed that HKa could prevent the co-localization of uPAR and EGFR. By immunoprecipitation, we proved that HKa could directly disrupt the complex of uPAR, integrins and EGFR. Mazzieri (Mazzieri et al., 2006) suggested that human cleavage-resistant uPAR does not activate ERK and does not engage FPRL1, but it activates an alternative pathway initiated by the formation of a ternary complex (uPAR-a3b1-EGFR) and resulting in the tyrosine autophosphorylation of EGFR. Gangliosides are thought to regulate epithelial cell adhesion and migration by inhibiting alpha(5)beta(1) integrin and EGFR signaling. Wang et al. (2005) reported that gangliosides inhibited the uPA-dependent cell migration by preventing the association of uPAR with alpha(5)beta(1) integrin or uPAR/alpha(5)beta(1) integrin with the EGFR. Moreover, a direct association of uPAR with a5b1 has been described and a 9-amino acid peptide composed of amino acids 240-248 of uPAR can directly bind to a5b1 (Chaurasia et al., 2006) . Substitution of a single amino acid within this region by alanine (S245A) in cell surface-expressed uPAR impaired its interaction with a5b1. Our data showed that uPAR was co-immunoprecipitated by both anti-EGFR antibody and anti-a5b1 and avb3 antibodies, whereas EGFR was co-immunoprecipitated by anti-a5b1 and avb3 antibodies. The reverse experiments precipitating with anti-EGFR and then western blotting for uPAR and integrins corroborated these results. HKa prevented the antibody to EGFR from precipitating uPAR and a5b1, suggesting that HKa completely disrupted EGFR-uPAR-a5b1 complex because EGFR and a5b1 might directly bind to uPAR. This observation was confirmed by reciprocal experiments. In contrast, HKa did not prevent the antibody to EGFR from precipitating avb3 and vice versa, indicating that EGFR, uPAR and avb3 formed a different complex, in which EGFR and uPAR bind to avb3 integrin.
In the process of transformation of a benign tumor to a malignant tumor, assembling of the local proteolytic machinery is a prerequisite. Prostate cancer cells can upregulate uPAR expression, which is the high-affinity receptor for pro-uPA (B1 nM), allowing uPAR to form a ternary complex with pro-uPA and EGFR. uPA not only serves as a component of the cell protease system, but also initiates the survival signals through EGFR pathway, which may be critical for tumor resistance to hormone ablation. In both cases, uPA could utilize either uPAR-EGFR or uPAR-integrin complexes to auto-activate and initiate a signaling pathway. This observation can explain that a single antagonist of EGFR produces a limited benefit in patient with prostate cancer. The disruption of the uPAR-EGFRintegrins complex by HKa might interfere with this transduction and suppress the activation of pro-uPA and signaling pathways initiated by uPA, which underscore its potential in prevention of tumor metastasis.
The metastatic spread of cancer cells is a dreaded complication of malignant neoplasms. Metastasis is a multistep process, in which malignant cells must initially migrate from the primary tumor, invade the surrounding tissue, and enter the vascular circulation (Li and Cozzi, 2007). If they are able to survive in the blood stream, they must then successfully arrest at a secondary target site, cross the vascular barrier, and migrate into the extravascular connective tissues. Subsequently, tumor cells may proliferate to form a clinically relevant metastatic colony. In the Figures 1 and 2 , we showed that HKa and D5 both inhibited cell migration and invasion of prostate cancer cells in a dose-dependent manner, which strongly indicated the potential of HKa and D5 to prevent the metastasis of prostate cancer cells as cell migration and invasion are the initial steps of tumor metastasis.
In this study, we first compared the inhibitory potency of HKa and D5 on tumor cell motility and invasion. We found that both HKa and D5 were potent inhibitors of tumor cell invasion, as they at 11.1 nM inhibited tumor invasion about 90%. As shown in Figure 1 , the inhibitory effect of HKa on tumor migration is more potent than that of D5, but both significantly slowed down the tumor motility. HKa and D5 mimicked the inhibitory effects of AG 1478 on tumor motility and invasion ( Figure 6 ), indicating HKa and D5 are alternative EGFR inhibitors. The molecular mechanism of HKa and D5 for exerting its inhibitory effects on tumor motility and invasion is that both HKa and D5 can bind to uPAR and block the association of uPAR and EGFR. This observation was verified by both immunofluorescence and immunoprecipitation experiments. Thus, our data showed the potential of HKa and D5 on the inhibition of prostate cancer metastasis.
Materials and methods
Reagents and antibodies
Two-chain high-molecular-weight kininogen was purchased from Enzyme Research Laboratories (South Bend, IN, USA). Collagen solution (purified rat type-1 collagen) was purchased from BD Biosciences (Bedford, MA, USA). Protease inhibitor cocktail was purchased from Sigma Co. (St Louis, MO, USA). Antibodies directed against total and phosphorylation-specific (S473) Akt, total and phosphorylation-specific (T202/Y204) ERK were obtained from Cell Signaling Technology Inc. (Beverly, MA, USA). Antibodies against total and phosphorylation-specific EGFR (Y1173), polyclonal antibodies against integrin av and b1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal antibodies against avb3 integrin (LM609) and a5b1 were from Chemicon (Temecula, CA, USA). Anti-uPAR mAb was from American Diagnostica Inc., (Stamford, CT, USA) . Rabbit polyclonal anti-uPAR antibody (DIIDIII) was a gift kindly provided by Drs Andrew Mazar and Graham Parry (Attenuon, LLC, San Diego, CA, USA). Vascular endothelial growth factor and bFGF was obtained from Invitrogen Corporation (Carlsbad, CA, USA). All other reagents were purchased from Sigma Chemical (St Louis, MO, USA) unless otherwise specified.
Preparation of recombinant D5 of HK
Glutathione-S-transferase (GST) and recombinant GST-D5 were prepared as described earlier (Liu et al., 2008b) . Briefly, GST was removed from GST-D5 by digestion with thrombin, which was inactivated with PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone). Free GST was removed with Glutathione Sepharose 4 Fast Flow column (Amersham Pharmicia Biotech, Piscataway, NJ, USA). Residual thrombin and PPACK were removed with Amicon Centriprep Bedford, MA, USA) . Using YM-10, D5 solution was exchanged into 50 mM HEPES, 150 mM NaCl, pH 7.5 buffer. Endotoxin levels in the preparations were determined with the chromogenic limulus amebocyte lysate assay by use of an endotoxin testing kit (Cambrex, Walkersville, MD, USA) . Endotoxin level in D5 was below detectable limits (o0.1 U/ml). D5 was visualized on 20% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and detected by western blotting as a single band.
Cell culture DU145, a prostate cancer cell line, was purchased from ATCC (Manassas, VA, USA). DU145 cell line was maintained in (DMEM) Dulbecco's Modified Eagle's Medium containing 10% fetal bovine serum, 2 mmol/l glutamine, 100 units/ml penicillin and 100 g/ml streptomycin and cultured in a humidified atmosphere of 95% air and 5% CO 2 at 37 1C. Zn þ þ (22.5 mol/l) were added to the culture mix whenever HKa and D5 were involved, as Zn þ þ is required for HKa and D5 binding to tumor cells.
Cell migration assay
Cell migration was assessed in 48-well Boyden chambers Corning Inc. (Corning, NY, USA) . The under side of membrane of the upper chamber was coated with a collagen mixture (10 g/ml, Calbiochem; San Diego, CA, USA) and DU145 (2 Â 10 4 ) cells in DMEM were seeded on the upper chamber. DMEM contained bFGF (20 ng/ml) was added to the bottom chamber. Tumor cells were allowed to migrate for 6 h (Katkade et al., 2005) . Then, the cells that remained in the upper chamber were removed using a cotton swab. The cells that migrated to other side of membrane of the upper chamber were fixed with 4% paraformaldehyde and stained with 1% toluidine blue. We counted cells in five fields ( Â 100 magnification) per well that essentially covered 80% of the well surface. The average number of cells from each of the triplicates represents the average number of cells that migrated in that treatment group. Each experiment had triplicate wells for every treatment group and we repeated each experiment three times. The mean of all results from controls was considered as 100%.
Cell invasion assay
Cell invasiveness was determined by the ability to transmigrate through a layer of matrigel in a Transwell chamber Corning Inc. Briefly, the 1:1 mixture (40 ml) of matrigel and DMEM was loaded on the top chamber of Transwell units. DU145 cells (20 000) were loaded on the top of matrigel. The medium þ 10% fetal bovine serum þ Zn (15 mM) was added to the bottom chamber of Transwell units. Twenty-four hrs later, cells were fixed by formaldehyde and stained by 1% toluidine blue. The cells that remained in the upper chamber were removed using a cotton swab. Cells that migrated to the underside of a membrane were counted as described in the section Cell migration assay.
Cell lysate preparation, immunoprecipitation and immunoblotting
Protein extraction, SDS-PAGE separation of proteins and western-blot analysis were performed as described earlier (Liu et al., 2004) . Cells were lysed in an M-PER mammalian cell protein extraction buffer (Pierce, Rockford, IL, USA) supplemented with Na 3 VO 4 (1 mM) and protease inhibitor cocktail and followed by freeze and thaw three times. After being kept on ice for 40 min, the extracts were centrifuged at 15 000 g for 15 min 4 1C. The supernatant was designated as the cell lysate.
The complex formation of uPAR with other signaling molecules was determined by immunoprecipitation according to the methods described by Nykjaer et al. (1997) with some modifications. Cell lysate was incubated with corresponding antibodies followed by incubation of protein A/G beads. The immunoprecipitates were subjected to SDS-PAGE under nonreduced conditions, and immunoblot analysis was performed as described below.
Separately, the immunoprecipitated complex or the cell lysate containing equal amounts of protein (10-20 mg) were solubilized in Laemmli's sample buffer (Bio-Rad, Hercules, CA, USA) and were subjected to SDS-PAGE. Separated proteins were then transferred onto nitrocellulose membranes. Membranes were blocked with 5% non-fat dry milk in Trisbuffered saline containing 0.05% Tween 20 and then probed with antibodies as indicated. Immunoblots were visualized by an enhanced chemiluminescence kit (Amersham Pharmacia Biotech) and analysed by densitometry. Data were obtained from three independent experiments.
Immunofluorescence microscopy
Cells grown on coverslips were treated as indicated in the Figure 3 legend. Cells were fixed and processed as described (Aguirre- Ghiso et al., 2001) . Cells were stained with anti-uPAR (murine monoclonal antibody, 4 mg/ml) and anti-EGFR (rabbit antibody, 2 mg/ml) antibodies in 0.1% bovine serum albumin/ phosphate buffered saline, or with vehicle alone. After washing and blocking, secondary antibody (FITC-conjugated anti-mouse IgG at 1:400, Sigma; AlexaRed-conjugated anti-rabbit IgG at 1:1000, Molecular Probes, Eugene, OR, USA) in 0.1% bovine serum albumin/phosphate buffered saline containing DAPI was added. Standard epifluorescence was captured with an Axioskop epifluorescence photomicroscope (Zeiss, Oberkochen, Germany).
Statistical analysis
Statistical analyses were performed by one-way ANOVA (analysis of variance) and all pairwise multiple comparison procedures (Student-Newman-Keuls method). Results were considered significant when P ¼ o0.05. The result presented as mean±s.e.m.
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